Clinical Trials Browser

Oligometastatic Prostate Cancer (OMPC)

Prostatic Neoplasms

Metastatic Castration-Resistant Prostate Cancer

Prostatic Neoplasms

Carcinoma, Transitional Cell

Prostatic Neoplasms

Carcinoma, Transitional Cell

Prostatic Neoplasms

Prostatic Neoplasms

Adenocarcinoma, Prostatic Neoplasms

Prostatic Neoplasms, Castration-Resistant

Non-Muscle Invasive Bladder Neoplasms

Prostatic Neoplasms

Metastatic Castration-resistant Prostate Neoplasms

Carcinoma, Carcinoma, Renal Cell

Urinary Bladder Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Prostate Cancer Metastatic

Prostatic Neoplasms

Urinary Bladder Neoplasms

Carcinoma, Renal Cell

Prostatic Neoplasms

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

Prostate Cancer Screening

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Brain Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Lung Neoplasms, Melanoma, Neoplasm Metastasis

Clear-cell metastatic renal cell carcinoma, Kidney Neoplasms

Carcinoma, Renal Cell, Kidney Neoplasms, Recurrence

Carcinoma, Renal Cell, von Hippel-Lindau Disease

Prostatic Neoplasms

Intermediate Risk Non-Muscle Invasive Bladder Cancer

Urinary Bladder Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Urinary Bladder Neoplasms, Recurrence

Prostatic Neoplasms

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Neoplasm Metastasis

Carcinoma, Renal Cell

Non-Muscle Invasive Bladder Neoplasms

Prostatic Neoplasms

Neoplasms, Prostatic Neoplasms

Stage I Mixed Cell Type Kidney Wilms Tumor

Non-muscle Invasive Bladder Cancer With Carcinoma in Situ

Prostatic Neoplasms, Recurrence

Carcinoma, Transitional Cell

Prostatic Neoplasms

Prostatic Neoplasms

Clinical Trials

PSMA-DC

OPTION-DDR

A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.

A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma

MK-5684-004

A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan Versus Standard of Care in the Treatment of Advanced Urothelial Cancer

Diagnostic Performance of [18F]PSMA-1007 PET/CT Imaging in Patients With Newly-Diagnosed Prostate Cancer

ASCENDE-SBRT

TRIPLE-SWITCH

KLK2-PASenger

MoonRISe-1

MK-2400-001

KLK2-comPAS

LITESPARK-033

TroFuse-031

CLARIFY

AMPLIFY

OMAHA-003

Solar-Stage

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study

STRIKE

Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial

GAIN-BCG

MUSIC-Screen

Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer

EvoPAR-PR01

Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain

Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma

LUTEON

MK-6482-043

Adjuvant Curcumin to Assess Recurrence Free Survival in Patients Who Have Had a Radical Prostatectomy

ABLE-32

Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)

MEVPRO-3

Salvage Moderate Hypofractionated Versus Ultrahypofractionated Radiotherapy for Biochemical Recurrence After Radical Prostatectomy in Prostate Cancer

EVER

PSMA-PET: Deep Radiomic Biomarkers of Progression and Response Prediction in Prostate Cancer

FORAGER-2

Neoadjuvant of Axitinib Plus PD-1 to Improve Disease Free Survival of Patients With Renal Cell Carcinoma

MoonRISe-3

EvoPAR-PR02

Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)

A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)

ABLE-22

MEVPRO-1

A Trial of SHR-A2102 With Adebrelimab in Locally Advanced or Metastatic Urothelial Carcinoma

REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac Trial

AcTFirst